Yseop announces the closing of a major strategic investment round, marked by the entry of Novartis as a new investor, and celebrates its participation in more than 150 clinical trials among the world’s leading pharmaceutical companies.
This is a big step forward for Yseop in its mission to fully automate the documentation process in the pharmaceutical sector – from preclinical testing to regulatory approval, including by the FDA.
Yseop, a participation supported by Grégoire Sentilhes, Michaël Strauss-Kahn and Gaëtan Leenhardt, is one of the world leaders in Generative Artificial Intelligence (Generative AI) for regulated industries, particularly pharmaceuticals. Yseop's SaaS solution makes it possible to transform complex data into natural language, by automating business rules and respecting the reliability and traceability requirements of demanding processes such as the documentary chain for marketing new drugs, clinical studies , financial reports…
In 2023, Yseop has generated more than 10 reports and eliminated tens of thousands of hours of writing and editing. These savings represent potential acceleration for the introduction of new drugs to the market and reinforce Yseop's commitment to bringing life-saving drugs to patients more quickly.
Read the press release: https://lnkd.in/dV__PxY6
